Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

60.43USD
17 Apr 2014
Price Change (% chg)

$0.47 (+0.78%)
Prev Close
$59.96
Open
$59.76
Day's High
$60.44
Day's Low
$59.63
Volume
1,611,403
Avg. Vol
1,356,996
52-wk High
$60.46
52-wk Low
$47.53

LLY.N

Chart for LLY.N

About

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in... (more)

Overall

Beta: 0.42
Market Cap (Mil.): $67,666.93
Shares Outstanding (Mil.): 1,119.76
Dividend: 0.49
Yield (%): 3.24

Financials

  LLY.N Industry Sector
P/E (TTM): 14.01 33.23 33.33
EPS (TTM): 4.31 -- --
ROI: 17.91 19.68 18.94
ROE: 28.92 20.37 19.69
Search Stocks

UPDATE 4-Japan drugmaker Takeda to fight $6 bln damages awarded by U.S. jury

* Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly

08 Apr 2014

US STOCKS-Wall Street opens flat ahead of earnings season

* Eli Lilly ordered to pay $3 bln in damages in Actos case

08 Apr 2014

US STOCKS-Wall Street set for flat open after selloff

* Eli Lilly ordered to pay $3 bln in damages in Actos case

08 Apr 2014

US STOCKS-Wall Street to edge higher at open after selloff

* Eli Lilly ordered to pay $3 bln in damages in Actos case

08 Apr 2014

US STOCKS-Futures slip as investors brace for earnings

* Eli Lilly ordered to pay $3 bln in damages in Actos case

08 Apr 2014

U.S. jury orders Takeda, Eli Lilly to pay $9 bln damages in Actos case -lawyer

April 8 - A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in punitive damages and Eli Lilly and Co to pay $3 billion in a case claiming that cancer risks to the diabetes drug Actos were concealed, the plaintiffs' lawyer said.

08 Apr 2014

EU backs J&J hepatitis C pill plus new drugs from Lilly, Takeda

LONDON - European regulators have recommended approval of a new pill for hepatitis C from Johnson & Johnson, underscoring the rapid development of oral treatment options for the liver-destroying disease.

21 Mar 2014

UPDATE 2-EU backs J&J hepatitis C pill plus new drugs from Lilly, Takeda

LONDON, March 21 - European regulators have recommended approval of a new pill for hepatitis C from Johnson & Johnson, underscoring the rapid development of oral treatment options for the liver-destroying disease.

21 Mar 2014

EU agency backs new drugs from J&J, Lilly, Takeda

LONDON, March 21 - European regulators said on Friday they had recommended approval of new pills for hepatitis C and diabetes from Johnson & Johnson and Eli Lilly , respectively, and an injectable drug for ulcerative colitis from Takeda.

21 Mar 2014

FDA spurns Lilly, Boehringer diabetes drug, cites factory problem

March 5 - Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed deficiencies at a manufacturing facility where it would be made.

05 Mar 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks